external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus.
Explore the latest updates from the life science industry.

BIOTECH

Magnetic Bead Separation: More Than Just a Magnet

We sit down with Sepmag's Lluís M. Martinez, Founder & CSO, and Josep-Maria Simó, Managing Director, to discuss the current state and future of magnetic separation technology.

Featured Articles.

PHARMA

Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal

PHARMA

The Current and Future State of Personalised Medicine

PHARMA

Novo Nordisk Announces Promising Results for CagriSema but Stocks Tell Different Story

BIOPROCESSING

Navigating the Digitalisation Journey in the Biopharmaceutical Industry

SUSTAINABILITY

A Modern-Day Noah's Ark?

PHARMA

Weighing the Cost of Semaglutide

BIOTECH

Immunocore Unveils Promising HIV Functional Cure Data at CROI 2025

HEALTH

Training the Immune System to Outlast Cancer

BIOTECH

Asimov and Revopsis Therapeutics Enter Strategic Licensing Agreement to Advance Gene Therapy Solutions

Latest News.

14th April, 2025

01. Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal

Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2.

8th April, 2025

02. Kandu Health and Neurolutions Merge to Transform Stroke Recovery

Kandu, Inc. merges Kandu Health and Neurolutions to create an innovative, integrated approach to stroke recovery, combining advanced technology with personalized, at-home care.

1st April, 2025

03. Cerevance Reports Phase 2 Results for Solengepras in Early-Stage Parkinson’s Disease

Cerevance has announced topline results from its Phase 2 ASCEND trial of solengepras, showing a small but non-significant improvement in motor symptoms and potential benefits for non-motor symptoms, with a strong safety profile.

27th March, 2025

04. Alys Pharmaceuticals Begins Phase IIa Trial for ALY-101 in Alopecia Areata

The pioneering immuno-dermatology company has announced the successful dosing of the first patient in its Phase IIa clinical trial for ALY-101, a novel treatment for Alopecia Areata.